The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...

Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...

Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.

This is the latest installment in a new series where BioPharma Dive uses data visualization to recap what’s going on across the industry. Today, we’re looking at Moderna’s stock performance in 2026 ...

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction, ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...

The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...